Menopause and hormone therapy in the 21st century: why promote transdermal estradiol and progesterone?

Pierre-Yves Scarabin¹, Marianne Canonico^{1,2}, Geneviève Plu-Bureau³, emmanuel oger⁴

¹Center for Research in Epidemiology and Population Health, INSERM, Villejuif, France

²Paris-Saclay University, Paris-South University, UVSQ, Paris-Saclay, Île-de-France, France

³Unité de Gynécologie Endocrinienne, Université de Paris, Paris, France

⁴EA 7449 REPERES (Pharmacoevidence and Health Services Research), Université de Rennes, Rennes, France

Correspondence to Professor Pierre-Yves Scarabin, Center for Research in Epidemiology and Population Health, INSERM, Villejuif 69372, France; pierre-yves.scarabin@inserm.fr

In their editorial,¹ Gersh and Lavie describe the many ways that estradiol impacts cardiovascular health. In addition, the authors rightly question the findings of the Women's Health Initiative among menopause women using hormone therapy. Importantly, they emphasise the need for using the most physiological human-identical transdermal estradiol combined with natural progesterone. However, no information is given on both the biological rationale and the expected benefits of transdermal oestrogens compared with oral oestrogens. Oral but not transdermal oestrogens result in a hepatic first-pass effect that may induce reversible prothrombotic changes in haemostatic variables,² including resistance to activated protein C (figure 1). Thrombotic

process plays a critical role in the development of both venous and arterial diseases. European studies have clearly shown the advantage of transdermal oestrogens with respect to the risk of venous thromboembolism³ and probably also stroke. The type of progestogens has also emerged as an important determinant of thrombosis. Progesterone has no effect on blood coagulation,² and it is the safest progestogen with respect to thrombosis.⁴ Since thrombosis is one main serious adverse effect of hormone therapy, women should be encouraged to use transdermal oestrogens combined with progesterone.

REFERENCES

- 1 Gersh FL, Lavie CJ. Menopause and hormone replacement therapy in the 21st century. *Heart* 2020;106:479–81.
- 2 Scarabin PY, Alhenc-Gelas M, Plu-Bureau G, et al. Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women. A randomized controlled trial. *Arterioscler Thromb Vasc Biol* 1997;17:3071–8.
- 3 Scarabin P-Y, Oger E, Plu-Bureau G, et al. Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk. *Lancet* 2003;362:428–32.
- 4 Scarabin P-Y. Progestogens and venous thromboembolism in menopausal women: an updated oral versus transdermal estrogen meta-analysis. *Climacteric* 2018;21:341–5.

Provenance and peer review Not commissioned; internally peer reviewed.

Patient consent for publication Not required.

Patient and public involvement Patients and/or the public were not involved in the design, conduct, reporting or dissemination plans of this research.

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests None declared.

Figure 1 Caption.